

ASX Announcement

27 August 2025

BCAL partners with Sonic Healthcare Australia to advance access to BREASTEST plus™

Highlights

- **Women can now attend one of 93 Sonic pathology centres across Sydney enabling local access to BREASTEST plus™**

BCAL Diagnostics Limited (ASX: BDX) ("BCAL") has entered into an agreement with Sonic Healthcare Australia Pathology Pty Limited, part of Sonic Healthcare Limited ("Sonic") to advance patient access to BCAL's blood-based cancer diagnostic test, BREASTEST plus™.

BREASTEST plus™, for women with dense breast tissue, has been successfully trialled through Sonic's network in Sydney since its launch in March 2025. Building on this success, this agreement formalises the commercial relationship to provide blood collection services for BREASTEST plus™ from 93 Douglass Hanly Moir Pathology collection centres in Sydney and specimen pre-analytical processing by Melbourne Pathology in Melbourne.

BCAL CEO, Shane Ryan, said: "This agreement with Sonic marks an important milestone in BCAL's commercial roll-out. By partnering with Sonic, we are making it convenient for women to have the BREASTEST plus™ blood test taken close to home helping both patients and clinicians alike. Quicker access to clinic and faster turnaround times aids better detection of disease and its management."

BCAL continues to progress the staged commercial rollout of BREASTEST *plus*™ in Sydney and Melbourne, with further expansion planned in the coming months.

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

BCAL CEO

Shane Ryan

sryan@bcaldiagnostics.com

+61 (0) 437192869

Media Relations

Rama Razy

rama.razy@automicgroup.com.au

+61 (0) 498 440 142

About BREASTEST *plus*[™]

BREASTEST *plus*[™] is the first product in BCAL's BREASTEST® range of non-invasive, lipid-based breast cancer diagnostics. BREASTEST *plus*[™] is a 'rule-out' test that has been designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

About BCAL

BCAL is an Australian biotechnology company dedicated to advancing early and accurate breast cancer detection. Our innovative, non-invasive blood test, the first in the BREASTEST® range of products, is designed to complement existing breast screening methods and provide additional lipidomic insights to rule-out breast cancer, empowering women and providing their clinicians with greater confidence in diagnostic outcomes. Improved screening accuracy potentially reduces the need for further investigation and biopsy resulting in better health outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.